{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T05:44:05Z","timestamp":1738129445384,"version":"3.33.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.ejphar.2008.02.002","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T14:43:17Z","timestamp":1202913797000},"page":"72-77","source":"Crossref","is-referenced-by-count":4,"title":["Effect of PPADS on achondroplasic chondrocytes: Inhibition of FGF receptor type 3 over-activity"],"prefix":"10.1016","volume":"584","author":[{"given":"Ana","family":"Guzm\u00e1n-Ar\u00e1nguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Crooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avner","family":"Yayon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Pintor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.02.002_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/1389450033490993","article-title":"Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia\u2014genetic short limbed dwarfism","volume":"4","author":"Aviezer","year":"2003","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2008.02.002_bib2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2174\/1381612003398528","article-title":"Fibroblast growth factors and their inhibitors","volume":"6","author":"Botta","year":"2000","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2008.02.002_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejphar.2008.02.002_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.105.088070","article-title":"The P2X3 antagonist P1, P5-di[inosine-5'] pentaphosphate binds to the desensitized state of the receptor in rat dorsal root ganglion neurons","volume":"315","author":"Ford","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.02.002_bib5","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1074\/jbc.270.6.2620","article-title":"Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix","volume":"270","author":"Guvakova","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2008.02.002_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1107\/S0907444900020813","article-title":"Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces","volume":"57","author":"Hecht","year":"2001","journal-title":"Acta Crystallogr., D Biol. Crystallogr."},{"key":"10.1016\/j.ejphar.2008.02.002_bib7","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1242\/jcs.02618","article-title":"Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis","volume":"118","author":"Krejci","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2008.02.002_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2174\/1381612023392973","article-title":"Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists","volume":"8","author":"Lambrecht","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2008.02.002_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1006\/jmbi.1998.1977","article-title":"Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas","volume":"281","author":"Lozano","year":"1998","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejphar.2008.02.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/002215549904700101","article-title":"Chondrocyte differentiation in a rat mesenchymal cell line","volume":"47","author":"Lunstrum","year":"1999","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ejphar.2008.02.002_bib11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1128\/MCB.20.2.516-522.2000","article-title":"The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation","volume":"20","author":"Monsonego-Ornan","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejphar.2008.02.002_bib12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1101\/gad.1179104","article-title":"Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype","volume":"18","author":"Murakami","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejphar.2008.02.002_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng0696-233","article-title":"Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia","volume":"13","author":"Naski","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2008.02.002_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/mol.51.2.277","article-title":"Diinosine polyphosphates, a group of dinucleotides with antagonistic effects on diadenosine polyphosphate receptor","volume":"51","author":"Pintor","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.02.002_bib15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1074\/jbc.M310384200","article-title":"Activation of the ERK1\/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes","volume":"279","author":"Raucci","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2008.02.002_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0022-3565(24)35298-X","article-title":"Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS), a putative P2Y(1) receptor antagonist, blocks signaling at a site distal to the receptor in Madin-Darby canine kidney-D(1) cells","volume":"292","author":"Shehnaz","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.02.002_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1006\/bbrc.1998.8262","article-title":"PPADS inhibits P2Y1 purinoceptors in rat brain capillary endothelial cells and in rat ileal myocytes by an indirect mechanism","volume":"244","author":"Vigne","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2008.02.002_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm971","article-title":"Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway","volume":"10","author":"Yasoda","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2008.02.002_bib19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0092-8674(91)90512-W","article-title":"Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor","volume":"64","author":"Yayon","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2008.02.002_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1749-6632.1999.tb09427.x","article-title":"Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors","volume":"886","author":"Zugmaier","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T15:28:37Z","timestamp":1738078117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0014299908001490"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.02.002","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}